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INTRODUCTION

The administration of 6-azauracil (as-triazine-3,5-dione; 6-AzU)
a decade ago to a group of patients with neoplastic disease was
complicated by the unexpected appearance of signs of central nervous
system toxicity.

1,2,3

Although this resulted in withdrawal of

6-AzU from clinical use, the cause of the unusual neurological
syndrome has continued to be a subject of interest and research.

4 5
5

In particular, the question has arisen whether the toxic effects on
the central nervous system are inseparably connected to the known
antimetabolic action of 6-AzU, or whether they are the result of
some unknown action of the as_-triazine ring per se. ^
In human subjects with neoplastic disease, oral administration
of 6-AzU in doses as small as 4.5 mg/kg/day resulted in the appear¬
ance of characteristic premonitory changes in the electroencephalo¬
gram after several days and lethargy, followed by somnolence, motor
abnormalities, psychic disturbances, and coma.

6

The most common

motor abnormality was hyperreflexia, but muscle weakness and twitching,
incontinence, choreiform movements, and tremor were noted in some
patients.

Psychic disturbances occurred in only about half of the

patients, and commonly included mental deterioration, hallucinations,
and in some patients euphoria and toxic psychoses.
of the 44 subjects became semicomatose or comatose.
slowly reversible on withdrawal of the drug.

t

About a quarter
All changes were

■

2-

-

Several patients had convulsive seizures after withdrawal.
Additional toxic effects

included thrombocytopenia and

leukopenia

during the course of administration in several of the patients.
ribonucleoside of 6-AzU,

6-azauridine

(6-AzUR)

The

is a much more effec¬

tive cytostatic agent and neurological disturbances have not occurred
with intravenous administration of as much as 600 mg/kg/day.
oral administration of 6-AzUR to patients results
in the
flora,

However,

in 80% absorption

form of 6-AzU, presumably because of the action of intestinal
7 8
’
and causes

the acute onset within a day of the

typical

encephalopathy usually seen after administration of 6-AzU.

Although

intravenous 6-AzUR is almost completely without toxicity in patients,
only partial remissions have been produced by it in several types of
adult acute

leukemias; experience with solid tumors has been less

g
encouraging.
-azauridine

6

Intravenous 6-AzUR and oral administration of triacetyl(21,3',5'-triacetyl-6-azauridine) have, however, been

remarkably successful in producing remissions

in severe psoriasis

9
and mycosis fungoides.
results

Administered orally,

in sustained blood levels of 6-AzUR;

excreted in the urine as 6-AzUR,
and only 3% as
17 patients

80% of the dose

is

the monoacetyl derivative,

the unchanged triacetyl derivative.^

In a series of

treated with this drug initially at 270 mg/kg/day for

1 to 3 weeks and then reduced to
as

17% as

triacetyl-6-azauridine

long as 6 months,

.
9
erate anemia.

135 mg/kg/day and maintained for

the only toxic manifestation was a mild to mod-

The neurotoxicity observed in two of these patients

receiving triacetyl-6-azauridine by mouth was attributable
of 6-AzUR (0.6%).

to an impurity

'

3-

-

Comparison of these effects
experimental animals

in human subjects

to those

is complicated by differences

in

in route and rate

of administration, and by problems of measurement of neurological
variables.

Some generalizations, however,

ing evidence

can be made;

for these will be reviewed subsequently.

pattern of neurological response
cats resembles

to 6-AzU in mice,

the support¬
The general

rats,

that observed in the human subjects;

dogs, and

the animals

become somnolent and comatose, and appear to develop both motor and
behavioral abnormalities.
however,

The dose required to elicit these responses,

is probably several orders of magnitude greater for the

laboratory animals.
in responding
tinguishable

Rats and mice also differ from human subjects

to intravenous 6-AzUR with neurological signs
from those caused by 6-AzU.

From studies using the

intraventricular route of administration it appears
nucleotide of 6-AzU, 6-azauridylic acid
logically active.

4

indis¬

(6-AzUMP)

that the ribo¬

is also neuro-

In both cats and human subjects

the effects of

small doses of 6-AzU appear to be cumulative over a period of days,
being neurologically equivalent to a single

large dose, but again,

as with the above observations, quantitative aspects have not been
studied in detail.
The changes

in the electroencephalogram are quite distinctive.

Both in cats, mice, and rats and in human subjects
reduction of fast wave activity,

these

reduction of photic response,
O

the appearance of large amplitude,
both groups

include

spiking slow waves.

these precede other neurologic changes.

/

’

and

1 Q

*

In

In cats and

4

-

rats

-

this pattern appears within an hour after intraperitonea 1 injec¬

tion of

1 to 3 gm of 6-AzU/kg.

The minimum amount, administered

either acutely or in repeated doses,
however,

is probably less.

of cats results
no change occurs
Novotny, e_t

required to produce

Similar changes

these changes,

in the electroencephalogram

from intraventricular administration of 6-AzUR,
from intravenous

al.

6-AzUR in patients.

4
but

8

have carefully measured several parameters of

central nervous system activity which have been useful in comparing
the effects of 6-AzU and 6-AzUR in mice, but which unfortunately are
of little help in com paring mice

to patients.

They found that

when 6-AzU was administered in a single intraperitoneal injection,
significant depression of exploratory activity occurred after 50 mg/kg;
anticonvulsant activity, especially against nicotine appeared at 200
to 400 mg/kg, analgesia at 700 mg/kg, motor incoordination at 900 mg/kg,
loss of righting reflex at

1550 mg/kg,

and death at 2200 mg/kg.

-AzUR by this route had the same effects, but at about 2 to 4 times

6

the dose.

No effect was noted on deconditioning of avoidance of

electric shock.

Morris and Glaser

have measured the maze running

ability of rats made ataxic by 1 gm of 6-AzU/kg and

found no signiO

ficant deficit in speed or accuracy.

The observation

that somnolent

patients appeared to be mentally clear after their attention was
aroused may be related.
The response to parenteral administration of 6-AzU by cats and
dogs

is similar to that of mice and rats;

muscular flaccidity and ataxia without

0.7 to 1.2 g/kg caused

loss of righting reflex.

5

-

-

In monkeys, however, no abnormalities of behavior or changes

in the

electroencephalogram were observed after oral administration of
mg of 6-AzU/kg/day for 4 days.

Although this dose

than that causing toxicity in patients,

it is

180

is much greater

small compared to

that

causing motor incoordination and electroencephalographic changes

in

mice.
Injection of 6-AzUR and 6-AzUMP into a lateral or the

fourth

ventricle allows more direct comparison of their relative activity
in brain tissue.

With some differences,

syndrome resembles

the resulting neurological

that observed clinically from 6-AzU.

Intraventri¬

cular administration of these drugs has not been performed in human
subjects.

The evidence of Novotny, et_ aJL.

suggests

that in mice

the relative activity of 6-AzUMP is greater than that of 6-AzUR, and
that both may be more active

than 6-AzU.

The effects

of direct intra¬

ventricular administration of 6-AzU, however, are not reported in the
literature.

Injection of 50 mg of 6-AzUR into the

ventricle of a cat

lateral cerebral

(of unstated weight) caused motor incoordination.

The concentration of 6-AztIR in various regions of the brain was
to 0.74 micromoles/gm of wet tissue, while
was 3 to 4% of this.

0.22

the concentration of 6-AzlJMP

Intraventricular injection of doses of 25 to 50

mg of 6-AzUR/kg in cats caused motor incoordination, often preceded by
outbursts of stereotyped movements,
head,

such as cleaning or shaking of the

followed in thirty minutes by sleep.

was observed at 5 to

12.5 mg of 6-AzUR/kg;

progressively incoordinated,

In rats a similar syndrome
outbursts of activity became

finally becoming a series

of muscular jerks.

6

-

-

This was elicited by only 1 to 5 mg of 6-Azump.

Larger doses of

these drugs usually caused only general depression.

The early

period of activity observed after intraventricular, but not intraperitoneal,

injection may just be a function of the region of the

brain effected.

Administration of

10 mg of 6-AzUR into the

1 or

fourth ventricle of cats each day for three days caused the appear¬
ance of lethargy, unsteadiness on the

feet, and after two days nystag¬

mus, extensor hypertonia, and myoclonic jerks.
occurred at both dosages

is unclear.

4

5

14

Whether or not this

In these

cats

istic changes in the electroencephalogram developed

the character¬

later;

this may

be related to the particular site of injection which is some distance
from midbrain and forebrain structures.
animals also closely resembles

14

The response of these

the response of patients

to 6-AzU

in that there was evidence of hyperactivity (myoclonic jerks)
accompanied by lethargy and incoordination.

In the above experiment

assuming that 30 mg of 6-AzUR was administered during the 3 days,
and that all of it remained in brain tissue as 6-AzUR or 6-AzUMP,
the concentration of triazine would have been roughly 0.5 micromoles/gm
An equivalent of 6-AzU entering the brain by the vascular route

in

rats would probably have caused only lethargy and a measurable
decrease

in exploratory activity.

This suggests

that 6-AzUR or

-AzUMP may be more active neurologically than 6-AzU.

6

be that particular centers are more

It may also

important in producing the

neurological effects, and that they are markedly effected by the
ventricular administration.
An unexplained observation in both patients and

laboratory

'

7-

-

animals is that younger subjects are more sensitive to the triazines.
This may in part be caused by the relatively smaller amount of body
tissue as compared to brain tissue in young animals, or may be related
to some biochemical or neurological difference in the developing
nervous system.
The anti-neoplastic activity of 6-AzUR

15-19

has been shown to

result from conversion iai situ to 6-AzUMP which competitively inhibits

19-22
orotidylic decarboxylase.

This same conversion and inhibition

occurs after administration of 6-AzUR in brain tissue of cats and rats.

4
Koenig, et al.,

have shown that in cat brain 6-AzUR is several times

more rapidly converted to the nucleotide than is 6-AzU.

Skold

23

has

measured the activity of the two enzymes responsible for these con¬
versions, uridine kinase and uridine phosphorylase, in extracts of
mouse brain and has found a similar pattern, the uridine kinase
being about three times more active.

There was some variation in

the ratio of the activities of these two enzymes in comparing other
tissues of mice and rats, and extrapolation of the above three
to one ratio to rat brain and human brain may be inaccurate.
Further evidence of species variation is shown by the complete
absence of the uridine kinase in the protozoa Trypanosoma equiperdum.
Other actions of the triazines need only be mentioned.

The

inhibition of polynucleotide phosphorylase by 6-AzUDP is of unknown

.

. .

.

, .

physiological importance.

25,26

r

.

In cat brain, however, the percentage

of the nucleotide which is phosphorylated to di- or tri-phosphates
is vanishingly small.

4

The inhibition of the incorporation of

amino acids into proteins reported to occur in pancreatic homogenates

24

8-

-

is

likewise of unknown significance.

26

The relative uptake of the base and the ribonucleoside
brain tissue from the bloodstream under various
not been extensively studied.
of the

conditions has

In cats, after intravenous

test solution to achieve constant blood

levels,

spinal fluid to blood ratio during perfusion of the
with artificial cerebrospinal fluid was
6-AzU, and 0.57 for glucose.

27

0.013

into

infusion

the cerebro¬

lateral ventricle

for 6-AzUR,

0.43

for

Comparison of the concetration of

6-AzU and 6-AzUR in the brain after intraperitonea 1 administration
of these drugs

is not possible from old data because of the very

low

22
uptake of the riboside by brain tissue.

Blood

levels of 6-AzUR

decrease very rapidly because of rapid excretion by the kidney.
This is probably another factor contributing to the

28

low uptake of

the riboside by brain tissue.
The metabolic fate of orotic acid is of central importance
this study.

The biosynthesis de_ novo of orotic acid was

in

first

extensively studied in bacteria by Kornberg and Liebermann over a
decade ago.

33 -36

The

pathway in mammalian tissue

is probably the

same, except that carboxymethyl hydantoin is not formed

(Figure

1).

37-40

Whether the orotic acid pathway is a major supplier of acidsoluble nucleotides
the only source.

in brain is obviously of importance;

The

therapeutic effectiveness of the

probably depends on the wide variation of various

it is not

triazines

tissues with

respect to their dependence on the synthesis of pyrimidines da novo.
Specifically, human neoplastic
are particularly sensitive

leukocytes and normal canine

to 6-AzUMP.

In these tissues,

leukocytes

the activity

9

-

-

of orotidylic acid decarboxylase

is high.

Probably the most con¬

vincing evidence of the degree of dependence of brain tissue on
synthesis de novo is

the previously mentioned study of Koenig,

4
et al. ,

in which

1 or

10 mg of 6-AzUR was administered into the

fourth ventricle of two cats

for 4 days and 0.112 micromoles of

6-^C-orotic acid was given three hours before sacrifice;

this

caused the incorporation of the radioactive orotic acid into acidsoluble pyrimidines of the hindbrain to diminish by 78 and 97%.
Most significantly,

the acid-soluble pyrimidine pool had been de¬

creased by about 50%.
ventricularly,

Since

the 6-AzUR was administered intra-

the inhibition of pyrimidine synthesis

in the

liver

was probably not significant, and exogenous pyrimidines were prob¬
ably available

to the brain.

That the neurological syndrome caused

by the administration of 6-AzUR may itself cause depletion of the
pool of acid-soluble nucleotides
ruled out, but the changes

in the brain cannot at present be

in pyrimidine metabolism are consistent

with the known mechanism of action of 6-AzUR in other tissues.
unexplained finding in Koenig's study was
inhibition of the

that despite

This suggests

bility of preferential incorporation of pyrimidines,
liver,

75 to 98%

incorporation of radioactive orotic acid into KNA,

the RNA pool size unchanged after 4 days.

the

An

into brain RNA.

Alternatively,

the possi¬

perhaps

from

the apparent sparing of

brain RNA may be a reflection of a relatively slow rate of turnover
of the RNA.

Other studies by Koenig

41 42
’
show that radioactive

orotic acid is actively incorporated into the RNA of neurons and
oligodendroglia.

Adams4-

has compared incorporation of radioactive

10

-

-

orotic acid and radioactive uracil into the KNA of the brains of
untreated young adult rats and comcludes

that these brains utilize

pyrimidines synthesized de novo for KNA synthesis.
Although it is probably the case
nucleotides

in the brain are

formed

are other potential sources.

that acid-soluble pyrimidine

largely from orotic acid,

Radioactive uridine

porated into uridylic acid and its derivatives
orotidylic acid decarboxylase

is

there

is rapidly incor¬

in cat brain when

inhibited by 6-AzUR.^

Geiger, ejt

44,45
al.,

have reported that the electrical activity of isolated,

perfused brains of cats
cytidine

is prolonged by the addition of uridine and

to the perfusion medium.

In hereditary orotic aciduria,

the genetic equivalent of 6-AzUMP blockade
neurological, as well as hematological,
proved by administration of uridine,
has been shown in rats

in human subjects,

the

symptoms are markedly im-

though not by uracil.

32

It

that both uridine kinase and uridine phosphory-

lase, which convert uridine

to uridylic acid and uracil to uridine

respectively, are present in brain, but as

in bone marrow and spleen,

in very low concentration compared to intestine.
centration of these enzymes

in the

23

The

local con¬

intestine, which receives exogen¬

ous uracil and uridine from the diet, may be related to the good
tolerance of the

intestine during administration of 6-AzUR.

46

The

ability of convert orotic acid to uridylic acid, on the other hand,
was greatest in the spleen.

In mice receiving 250 mg of 6-AzUR/day

for a month the spleen became smaller,
lymphoblasts decreased,
However,

the number of

lymphocytes and

and atypical mitotic activity appeared.

in this group of mice,

there were also marked changes

47

in

-li¬

the

intestinal mucosa, and it is

generalize

therefore obviously unsafe

to

that tissues with active synthesis of pyrimidines

from

orotic acid and with relatively low uridine kinase activity are
more severely effected by 6-AzUR.

Although uracil incorporation

into the acid-soluble pyrimidine nucleotides
tively slow,

of rat brain is rela¬

this may be an artifact of measurement caused by the

relatively large pool of uracil, as pointed out by Canellakis in
his studies with rat

liver.

29

In order to estimate the degree of blockade of orotidylic
acid decarboxylase using the method described below,

it is

to know that the only pathway utilized for the metabolism
radioactive orotic acid is

important
the

toward synthesis of uridylic acid.

The

equilibrium of the reaction catalyzed by purified dihydroorotic acid
dehydrogenase of Zymobacterium oroticum strongly favors
dihydroorotic acid.

34

A number of observations suggest, nevertheless,

that this pathway is not used by mammalian tissues
carbamyl-L-aspartate

formation of

in vivo;

48

in liver,

is catabolized only one-fifth as rapidly as orotate

both 5-azaorotic acid and 6-AzUMP can almost completely block catabolism
of orotic acid;

in tissue homogenate studies

1-pyrophosphate

in the medium is necessary for any catabolism of orotic

acid.

in vitro,

In the brain of the cat it is also possible

5-phosphoribosy1-

to decrease

the

incorporation of radioactive orotic acid into acid-soluble derivatives
by as much as 98% by administration of 6-AzUR.

If alternative path¬

ways were available for the metabolism of orotic acid,
should have appeared in the acid-soluble

fraction.

radioactivity

On the other hand,

-

12

-

-

one study has shown that the specific activity of uracil as compared
to uridylic acid in rat brain
cantly

(but not in rat

liver)

is signifi¬

increased after the administration of radioactive orotic

49

acid.

This suggests either that there

of UMP in the brain,
uracil.

is a heterogenous pool

or that orotic acid is directly converted to

The amount of radioactive uracil derived directly from

orotic acid was probably quantitatively unimportant in the present
experiment

(see below); however,

the amount of uracil which was

rapidly lost from brain tissue or rapidly converted into uridine,
uridylic acid,

or j3-alanine was not measured.

The mechanisms controlling the metabolism of orotic acid have
been studied in microorganisms and mammals.

When Escherichia coli

mutants with a block in pyrimidine synthesis are grown in a medium
limited in pyrimidines,

there

is an increase

in the production of

the enzymes catalyzing the synthesis of pyrimidines,
because of the release of end-product repression.
control known to be active
ity of aspartate

in rat

liver is

32

probably

A mechanism of

inhibition of the activ¬

transcarbamylase by various uridine and cytidine

derivatives, deoxyribonucleosides, and purine deoxyribonucleotides.^
Dihydroorotase is also subject to some degree of inhibition by these
products.
acid.
the

52

Orotidylic acid decarboxylase

An indication of the effectiveness of these mechanisms

increase

is

in the excretion of orotic acid from one milligram to

more than 8 grams within several days
6-AzUR.

is inhibited by uridylic

in patients

treated with

The accumulation of endogenous orotic acid in tissues after

blockade by 6-AzUR would complicate

the

interpretation of studies

.

13

-

-

utilizing radioactive orotic acid as a precursor.
of endogenous orotic acid would dilute
administered orotic acid, and the

A large amount

the radioactivity of the

inhibition of the metabolism of

orotic acid would appear falsely high.

On the other hand,

the

mass effect of an increased amount of orotic acid would tend to
accelerate

its metabolism and to compete with the inhibitor, and

the effectiveness of the inhibitor would appear falsely low.
concentration of orotidylic acid,

the

acid, may also be similarly increased,

The

immediate precursor of uridylic
since orotidine excretion in

the urine of patients treated with 6-AzlXR is also markedly increased.
The problem of dilution is probably not encountered in this
however,

study,

since the amount of radioactive orotic acid is probably

relatively great, and the

time course short

Since brain tissue shows

(see discussion below).

considerable dependence on the meta¬

bolism of orotic acid for its supply of pyrimidines, and since
reactions are strongly inhibited by administration of 6-AzU,
reasonable

to connect the behavioral effects with this

Nevertheless,

another dose-dependent effect of the

these

it is

inhibition.

4 5
5

triazines unre¬

lated to their antimetabolic activity is difficult to rule out.
Because of the structural and pharmacological similarities of the
triazines

to barbiturates, a barbiturate-like effect has been

postulated.
cussed

6 11
*

later.

Evidence suggesting this comparison will be dis¬
The approach taken in the

following experiment is

the much easier task of demonstrating that equivalent inhibition of
the metabolism of orotic acid

(and therefore of pyrimidine synthesis)

in the brain by another pyrimidine analog is not associated with

14

-

neurological signs.

-

Another structural analog of uracil,

(svm-triazine-2.4-dione;

5-AzU), which has been shown to have anti-

tumor and antibacterial activity,
the metabolism of orotic acid.

56

17 54 55
5
*
is also capable of inhibiting
Although

less extensively studied,

5-AzU does not appear to cause abnormalities
central nervous

5-azauracil

in the

function of the

system.

The action of this symmetrical triazine is probably inhibition
of both orotidylic acid decarboxylase and orotidylic acid pyrophosphorylase.

Using a par tide-free extract of mouse

56
macher"” has shown that release of

liver, Handschu-

14,
from 7-"C-orotic acid was

_3
inhibited 78% by 2 x 10
of 5-AzU release of

14

M 5-AzU, and that at the same concentration

CO^ from 7-

inhibited, but by only 47%.
complex, however,

buffer at 37° the base
spontaneously.

58

C-orotidylic acid was also

The mechanism of this action may be

since 5-AzU is

6-AzU,^ and in addition,

14

to some extent metabolized

the ring structure

is unstable.

like
In a pH 7.4

is hydrolyzed to N-formylbiuret and biuret

The N-formylbiuret is known to inhibit dihydroorotase

in Escherichia coli and to have significant antibacterial and antimitotic effects.

59

Another action of 5-AzU is inhibition of uridine

phosphorylase and deoxyuridine phosphorylase.
hour course of the

60

During the three

following experiments, however, non-enzymatic

degradation of 5-AzU would have been only 10 to

15%, and the con¬

centrations of the metabolites required for inhibition are

large.

15

-

-

MATE RIALS

The solvents used in paper chromatography were prepared
as

follows:

(1) n-butanol, acetic acid, and water,

n-butanol, pyridine, and water,

1:1:1;

(3)

ammonium hydroxide, and water, 85:1.3:15;
86:14; and
75:5:25.

(5) ethanol,

5:1:2; '(2)

iso-butyric acid,

2N

(4) n-butanol and water,

concentrated ammonium hydroxide,

and water,

A descending solvent front of 40 to 50 cm on Whatman #3

paper was used for all studies.
The 5-AzU and 6-AzU were obtained from the Cancer Chemotherapy
National Service Center.

Chromatography in solvent systems

and 3 showed no ultraviolet-absorbing impurities.
orotic acid was prepared by Dr. P. K.

Chang,

1,2,

The 2-^C-5-aza-

the 2-^C-orotic acid

was obtained from New England Nuclear Corp., Boston, Mass.,and the
2-

14

C-6-azauracil was obtained from Volk Radiochemical Company,

Burbank, Calif.

Chromatography in solvent systems

1 and 2 indicated

that the purity of these radioactive compounds was at

least 97 to

98%.
Radioactivity of solutions and papers was assayed by liquid
scintillation as previously described.

61

.

16

-

-

METHODS

General
All experimental animals were Charles River Sprague-Dawley
white male rats weighing between 55 and 70 gm.

In all experiments

the freshly-prepared, warm solutions of 5-AzU or 6-AzU were admin¬
istered by intraperitoneal injection of three equally divided doses
one-half hour apart, totaling 2.0 gm/kg of body weight.

For purposes

of discussion, the time elapsing after injection is always figured
from the final injection.

The pKa1s of 5-AzU and 6-AzU are 6.7

and 7.0 and by calculation the isotonic pH 7.4 solutions contain
19.1 and 20.4 mg of triazine/ml, and 0.141 and 0.129 ml of IN NaOH/ml
respectively.

These solutions were prepared and their pH adjusted

to 7.4 with small amounts of NaOH.

Peritoneal washings showed less

than 10% of either drug remaining free in the peritoneum one hour
after the injections.

Control animals received warm 0.9% saline,

200 ml/kg of body weight in three divided doses one-half hour apart.

Behavioral parameter
The 6-azauracil, 5-azauracil, and saline were administered
above to six animals and the righting reflex was measured every 15
minutes.

Loss of the righting reflex was considered complete when

animals did not right themselves within 30 seconds after being placed
back down on a hard surface.

Activity, muscle tone, and coordination

-
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were observed at

10 minute

-

intervals but not quantitated in the

three groups.

Tissue distribution
(a)

5-AzU.

2-^"C-5-azauracil was prepared from 2-^C-5-aza-

orotic acid by treatment with 0.5 N HC1 for 30 minutes at 50°.
main product of the reaction was
in solvent systems 2,4, and 5.

The

shown to have the same Rf as 5-AzU
It was purified by isotopic dilution

with 5-azauracil and recrystallization from boiling methanol.
graphic analysis

in solvent

Chromato

1 showed 99.1% of the radioactivity in

the ultraviolet-absorbing 5-azauracil spot, and

less

than 0.3% in

the regions known to contain the decomposition products of 5-azauracil.
Isotonic pH 7.4 solutions containing the

14

C-labelled compounds were

prepared and administered as described above.
sacrificed at

The animals were

1,2, and 4 hours by withdrawal of blood from the abdom¬

inal aorta under ether anaesthesia.

Solid tissues were homogenized

with 5 volume of 0.5 N perchloric acid and blood homogenized with 3
volumes of 5% trichloroacetic acid.

After centrifugation for

15

minutes at 4000 x g the radioactivity of the supernatant solution
was measured.

Respiratory gases were analyzed for

animal for 4 hours.

Urine was collected and analyzed by paper

chromatography with solvents
(b)

6-AzU.

except with the

in one

1 and 5.

The procedure was
four animals

identical to the above

sacrificed at 2 hours.

for 5-AzU

From these animals

a pH 7.0 extract of whole brain was prepared as described below, using

5

volumes of 5 N perchloric acid at 0°.

This was

lyophilized,

recon-

-In¬

stituted with sufficient water
aliquots containing about
paper.

to dissolve

the solids at 40°, and

1700 counts per minute were spotted on

Paper chromatography in solvent systems

1,2, and 3 and grad¬

ient elution chromatography using Dowex 1x4 200 mesh columns with
a 2 N ammonium formate eluant

was

also performed.

radioactive peak from this column was

lyophilized,

white solid dissolved in water, and its
using solvents

1,2, and 3.

Both the

the resulting

identity with 6-AzU confirmed

The acid-insoluble residue containing

the KNA was washed an additional 6
chloric acid.

The single

times with 5 volumes of 0.5 N per-

fifth and sixth wash were

Following successive dehydration with
lute alcohol, a boiling mixture of

free of radioactivity.

10 volumes of 95% ethanol, abso¬

1 part absolute alcohol and 3 parts

ether, and finally anhydrous ether, a fine white powder was obtained.
This was dissolved in 3.0 ml of 0.3 N NaOH/100 milligrams of powder
and incubated at 37° for 24 hours.
excess of 12 N HC1 to about pH 6,

Neutralization with a slight
addition of

1 volume of absolute

alcohol, and centrifugation in the cold yielded a clear supernatant
fluid which was assayed for radioactivity (150 minutes

for each sample)

and ultraviolet absorption at 260 and 280 millimicrons.

Tissue slices
Untreated rats were anaesthetized with ether, exsanguinated via
the abdominal aorta, and the brain rapidly excised.
were

Tissue slices

taken from the cerebral cortex such that each hemisphere yielded

about 4 slices of gray tissue weighing

125 mg.

The slices were

imme¬

diately transferred to rubber capped center-wall flasks containing

19

-

-

14
0.1 micromoles of 7per ml,
slices

and Krebs

5
C-orotic acid,

III solution

62

8 x 10

counts per minute

to a final volume of 2.0 ml.

from one hemisphere served as a control;

6-AzUR were added to the other.
of 2 N NaOH.

Flasks were

The

5-AzU, 6-AzU, or

The center-we 11 contained 0.2 ml

incubated with shaking for 30 minutes at

37° and the reaction stopped by injection of 0.5 ml 6 N perchloric
acid.

The flasks were shaked for an additional 15 minutes

the complete release of

14

C02«

Reagent blanks were

treated similarly.

The NaOH in the center well was assayed for radioactivity.
tions were performed for 60 minutes
of

14

C02 was increased by only 50%,

rate with

longer incubation periods.

instead of 30 minutes,
thus

to assure

If incuba¬
the release

indicating a decreased reaction

Two rats received the standard

pretreatment with 5-AzU and 6-AzU, and after 2 hours
from each hemisphere were incubated as above

tissue slices

to determine

the

effect of treatment in vivo on activity _in vitro.

Metabolism of 2-

14

C-orotic acid in vivo

The following procedure was performed four times, each time
on a group of six rats
saline.

One hour after the third injection of the

saline each rat was
+ 0.002 ml of 2was

treated with 5-azauracil, 6-azauracil, or

14

triazine or

lightly anaesthetized with ether and 0.05 ml

C-orotic acid, 9.0 micromoles/ml, 30 microcuries/ml

injected into the cisterna magna through a #27 gauge needle

fitted with a metal disk 3/16 of an inch from the

tip.

Animals

treated with 5-AzU or saline rapidly awakened after or during the
✓

twenty second injection period, but those

treated with 6-AzU, responding

20-
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only sluggishly to the noxious stimulus of the ether in the first
place, remained unresponsive and tachypneic until the time of
sacrifice one hour later.

In nine of ten control animals an

injection of Evans Blue dye was distributed throughout the subarach¬
noid space.

In the radioactivity studies, of the twenty four ani¬

mals injected with ratioactive orotic acid, three were excluded,
one because of leakage at the injection site, and two because the
total recovery of acid-soluble radioactivity was over 5 standard
deviations lower than the mean for their group.
One hour after the injection of radioactive orotic acid, the
rats were anaesthetized with ether and rapidly exsanguinated via
the abdominal aorta.

The brain was removed immediately, cut into

six pieces to open the ventricles, washed three times in ten
volumes of ice-cold 0.9% saline, blotted, weighed, homogenized in
two volumes of 0.5 N perchloric acid at 0°, centrifuged for fifteen
minutes at 4000 x g at 0°, and the clear supernatant fluid removed.
A second supernant fraction was similarly prepared from the residue,
combined with the first, and assayed as the acid-soluble fraction.
This was neutralized with 5 N potassium hydroxide, weighed in tared
tubes to determine the volume, and the total radioactivity deter¬
mined by scintillation counting.

The acid-insoluble residue was

washed at 0° five times with 10 volumes of water (first two groups)
or 10 volumes of 0.5 N perchloric acid (second two groups).

In

three of the four groups of 6 animals the final wash contained no
radioactivity; one group was discarded because of inadequate wash¬
ing.

The dried, defatted residue containing the DNA,RNA and protein

'
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was hydrolyzed with sodium hydroxide as described above.

The amount

of incorporation of radioactivity into RNA per mg of dried,
tissue was calculated,
To measure

defatted

and compared to the control in each group.

incorporation into DNA,

the residue

from the

first

hydrolysis was rehydrolyzed with the same volume of 0.3 N sodium
hydroxide

for four hours at 37

o

, and reprecipitated again by

neutralization and addition of alcohol.
three

times with

for 30 minutes

This residue was washed

1% trichloroacetic acid at 0° and heated at 85°

in 5% trichloroacetic acid.

After centrifugation,

the radioactivity of the supernatant solution was measured.
The

liver was homogenized in 2 volumes of cold 0.5 N perchloric

acid, centrifuged at 4000 x g for

15 minutes at 0°, and the radio¬

activity of the supernatant fraction measured.

Blood was

treated

similarly except that 3 volumes of 5% trichloroacetic acid was used
for extraction.

Urine was collected under wire screens at the bot¬

tom of beakers and the radioactivity determined.
Aliquots of the acid-soluble extract from the brain were
analyzed in two ways; by isotopic dilution with carrier orotic acid
after hydrolysis with acid to convert orotidine and orotidylic acid
to orotic acid; and by paper chromatography.
(a)

Isotopic dilution.

hydrochloric acid at

100

o

for

One ml aliquots were
15 minutes

treated with 6 N

in stoppered tubes

to

completely hydrolyze orotidylic acid and orotidine to orotic acid.
The kinetics of this hydrolysis were studied using a Spectrocord
500 recording spectrophotometer.

Orotic acid

(50 mg) was added,

dissolved by the addition of NaOH, and precipitated again by the
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addition of HC1.

-

The precipitate was crystallized twice from

boiling water, yielding 15 to 20 mg of fine white powder.

This

purified orotic acid was dissolved in 1 N sodium hydroxide and
aliquots were

taken for determination of radioactivity and absorp¬

tion of ultraviolet

light at 260 millimicrons and 280 millimicrons.

From these data the

total concentration of orotic acid,

orotidine,

and orotidylic acid in the perchloric acid extract could be calcu¬
lated.

The purity of the orotic acid was

a third recrystallization;

checked in one group by

the specific activity remained unchanged.

Paper chromatography with solvent systems

1 and 2 showed 90% of the

radioactivity contained in the wide ultraviolet-absorbing band of
orotic acid and
(b)
the

10% non-specifically distributed.

Paper chromatography.

A total of twelve samples

four groups was chosen for the more extensive analysis.

from
The

acid-soluble extract after adjustment to pH 7 was resolved satis¬
factorily by two chromatographic systems,

1 and 2.

In addition,

aliquots were hydrolyzed by treatment with 6 N HC1 at
minutes and also by treatment with

100° for 15

1 N HC1 for 30 minutes.

hydrolyzed extracts were evaporated to dryness

The

in vacuo at 40°,

reconstituted with water, and analyzed by chromatography with sol¬
vent 2.

The consistency of these results was

sample in solvent system 3.

confirmed for one

For each chromatogram,

50 microliters

of the sample was mixed with 25 micro liters of a solution containing
orotidylic acid, orotidine,

orotic acid, uridylic acid, uridine,

and uracil at sufficient concentrations
ultraviolet absorption.

to be detectable by their

The chromatograms were cut into

10 to

15
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pieces, based on the positions of the authentic compounds.

The

radioactivity of the sections was determined by scintillation
counting as previously described.
Except when otherwise

indicated,

the data is reported with each result.

the standard deviation of
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RESULTS AND DISCUSSION

Behavioral parameter
After administration of 2 gm of 6-AzU/kg by intraperitoneal
injection, rats

lost the righting reflex within 30 to 60 minutes

(after the third divided dose) and became unresponsive
stimululation or to pinching of the
ments,

foot.

However,

in later experi¬

it was noticed that these rats did show some sluggish response

to anaesthetization with ether.

The range of time

recovery of the righting reflex was

in activity,

for complete

two to seven hours.

treated with saline or 5-AzU there was no ataxia,
crease

to corneal

In the rats

flaccidity, de¬

or slowing of the righting reflex as was observed

in those receiving 6-AzU.

Tissue distribution
In comparison with 6-AzU,

the 5-AzU was very rapidly eliminated

from the blood stream and achieved lower
vous system (Table 2).

levels

in the central ner¬

The concentration of 5-AzU in tissues other

than the brain dropped precipitously after the
hour after receiving the

first hour.

One

third divided dose of 2-^C-6-azauracil

the concentration of radioactivity in the acid-soluble
the brain was 3.1 micromoles/gm while

fraction of

that of the animals

2-^C-5-azauraci 1 was only 0.5 micromoles/gm.

receiving

Of the radioactivity

recovered from the animals receiving 6-AzU, most was unchanged 2-^C6-AzU (see below).
was made
5-AzU.

Because of the

to determine

low specific activity, no attempt

the extent of the metabolism of radioactive
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The poor penetration of 5-AzU into brain tissue may be partly ex¬
plained by its acidity.

At pH 7.4 only 17% of the 5-AzU is present

in the uncharged acid for, compared to 29% of 6-AzU.

The marked

drop in the blood concentration of 5-AzU during the second hour to
about

10% of the one hour level may explain why the brain concen¬

tration failed to rise during this

time.

Plasma

significantly higher than those of whole blood,
the compound freely permeates erythrocytes.
markedly less

levels were not
suggesting

that

Urine output seemed

in the animals receiving 6-AzU than in the others,

and was often not detectable.

The

total excretion of the radio¬

activity, presumably as 2-^C-6-AzU,^^ varied widely from 3% to
44% of the

injected dose after 2 hours.

Although the concentrations

of 6-AzU in the brain in the animals sacrificed after 2 hours only
varied by 8%,
great at 50%.

the range of concentrations in other tissues was as
The urinary excretion of 5-AzU after 2 hours was only

42% of the injected radioactivity,
recovered from this animal.

but the bladder urine was not

Chromatography of this urine using

solvent system 1 showed that 60% of the 5-AzU was excreted unchanged.
The total recovery of the respiratory ^CC^ from the animal treated
with 5-AzU was

less

The results

than 0.4% of the

injected dose after 2 hours.

from both paper and column chromatography of the

perchloric acid extract of the brain of one of the
sacrificed after 2 hours

indicate

four animals

that the rate of metabolism of

the administered 6-AzU is very slow in brain tissue.
analysis of the acid-soluble extract
allowed good resolution of 6-AzU,

Chromatographic

in solvent systems

6-AzUR,

1 and 3

6-AzUMP, and glyoxylic
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acid semicarbazone,

the primary metabolites of 6-AzU,

vealed a single radioactive peak.

The main peak of the acid-

soluble extract was split in solvent 2.
was caused by the

and re¬

This splitting, however,

interference of salts and other compounds

the neutralized acid-soluble extract,

in

since when the single peaks

from the other two chromatograms were eluted and analyzed using
solvent system 2,

they moved as a single peak.

This major peak

contained 97.5% of the total radioactivity of the perchloric acid
extract and had Rf's identical with

those of 6-AzU.

bolites were present in low concentration:
6-AzUMP,

0.5%+ 0.2%;

6-AzUR,

0.7% + 0.2%;

glyoxylic acid semicarbazone,

0.4% + 0.2%.

(The mean and the range of the
analysis

in solvent systems

represent upper

The other meta¬

two values

1 and 3 are

from chromatographic

indicated).

These values

limits of activity for the respective metabolites.

Recovery of radioactivity after column chromatography was 98%;
one peak was detected.

Paper chromatography in solvent systems

2, and 3 showed 98.0 + 1.7% of this activity was 6-AzU;

only
1,

there were

no other significant peaks.
Incorporation of radioactivity from 6-AzU and 6-AzUR into
brain RNA has been reported by Koenig, e_t
ditions

in this experiment,

al.

,

4

but with the con¬

incorporation of radioactivity was not

significant.

Although radioactivity was detected in one of the RNA

hydrolysates,

the combined data for the

+ 0.0039 micromoles of the

label from 2-

recovered per 1 gm of we brain tissue.

four rats showed only 0.0012
14

C-6-azauracil in the RNA

Compared with

the

total
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recovery of acid-soluble radioactivity from the brain, this is less
than 0.1% incorporation into KNA.

Tissue slices
The above data raised the question whether the concentrations
of either 5-AzU or 6-AzUMP in the brain were sufficient to inhibit
synthesis of uridylic acid.

A somewhat equivocal answer was obtained

by measuring the release of radioactive CO2 from 7by slices of cerebral cortex (Figure 2).

14

C-orotic acid

This assay is sensitive to

inhibition of orotidylic acid pyrophosphorylase or orotidylic acid
decarboxylase.

Although in this system both 5-AzU and 6-AzUR did

inhibit decarboxylation, the later was 100 times more effective.

At

the observed concentration of 5-AzU in brain tissue, inhibition was
only about 20%.
concentration.

6-AzUR inhibited decarboxylation by 50% at 3 x 10
At 30 times this concentration 6-AzU was ineffective,

suggesting a much slower rate of conversion to 6-AzUMP.

Metabolism of 2-

14

C-orotic acid in vivo

5-AzU, 6-AzU, or saline were administered to rats in the usual
manner, and at the time when the animals in the group which was given
6-AzU became comatose (that is, after 1 hour), 0.5 micromoles of
2-

14

C-orotic acid was injected into the cistema magna of all animals

(the details of this procedure are presented under "Methods").

The

interpretation of the results requires consideration of several
incompletely understood variables.
Since both triazines inhibit the activity of the enzymes between
orotic acid and uridylic acid (Figur 1), the parameter of interest is
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the rate of conversion of orotic acid to uridylic acid.
controlled system for comparison of the
by 5-AzU or 6-AzUMP have
(2)

a large

(1) just the

(and therefore constant)

dylic acid, and

(3)

2-

14

A completely

inhibition of this conversion

two enzymes and co-factors,
amount of nonradioactive uri-

C-orotic acid, and

(4)

inhibitor.

Although

accurate determination of this parameter requires more

than one

measurement, an approximation can be made by measuring

the extent

of the

(partial) conversion of the radioactive orotic acid to radio¬

active uridylic acid in a given period of time.

Isotopic dilution

with carrier orotic acid is a convenient method for measuring

the

amount of radioactive orotic acid which has not been metabolized
during the reaction period.
before

Acid hydrolysis of the reaction mixture

isotopic dilution will add a small amount of radioactivity

by converting orotidine and orotidylic acid to orotic acid;
subtraction of this value
reaction mixture,
lated.

from the

by

total radioactivity of the

the amount of uridylic acid formed may be calcu¬

The reaction from orotidylic acid to uridylic acid is
4

essentially irreversible.
The first two of the above conditions are clearly applicable
to the situation in the experimental animals.
enzyme, orotidylic acid pyrophosphorylase,
metabolism of orotic acid in the brain,
is no evidence

Probably only one

is responsible

for the

(see Introduction).

There

that orotidine or orotidylic acid are metabolized

to any product other than uridylic acid or orotic acid.

Although

chromatographic studies did not resolve and identify all the metabolic products of 2-

14

C-orotic acid, activity associated with
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dihydroorotic acid was not above background, and there were no
areas of unexplainable radioactivity.

The possibility that

orotic acid is directly decarboxylated to uracil has been raised.
However, uracil was only about 20% of the
peak designated as uridine plus uracil.

imperfectly resolved
Unless uracil was very

rapidly lost from brain tissue, any direct contribution from orotic
acid not passing through uridylic acid would have been quantitatively
insignificant.

The results of the chromatographic analysis of the

urine of 3 animals

in this study support the

idea that uracil does

not enter the general circulation to a significant extent in one
hour.

Over 97% of the radioactivity in the urine of the animals

administered 5-AzU or 6-AzU was
orotic acid in solvent systems

identified as unmetabolized 21 and 2.

14
C-

If the excretion of radio¬

active uracil in the urine of these animals had occurred to the
extent of l/20t^1 of the amount of the sum of uracil and uridine
recovered in the brain (see

figure

On the other hand, only 70 to
of the control animal was 2-

14

2),

it would have been detectable.

75% of the radioactivity in the urine
C-orotic acid, and 25

to 30% was de¬

tected in unidentified metabolites, an amount about equal to only
about

1/5

of the amount of the sum of uridine and uracil recovered

from the brain in this animal.
relatively large

29

In the

liver,

the pool of uracil is

and significant incorporation of radioactivity

into uridine and uridylic acid from uracil would not be anticipated.
If the pool of uracil in the brain is also

large,

then the relative

increase of the uracil plus uridine peak in comparison with that of
the uridylic acid and higher phosphate and sugar derivatives

in the
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animals given either triazine was
increase of uridine, not uracil

largely attributable

to a relative

(Figure 3).

It is also obvious that uridylic acid was much more abundant
than 2-

14

C-orotic acid since

compounds

the concentration of all radioactive

in the brain was probably only about 0.03 micromoles/gm
14

on the average, and the amount of 2probably less.

C-orotic acid at any time was

The concentration of uridylic acid should have been
4

at least
change

10 times this.

Furthermore,

there

is probably little

in the pool of uridylic acid during the experiment,

in Koenig's cats,

since

80% inhibition of orotic acid metabolism by 6-AzUR

for 3 days resulted in only about a 50% reduction in pool size.
The third condition presents

the most perplexing problem since

the concentration of endogenous orotic acid, while of considerable
theoretical importance,

is unknown.

Although it seems worthwhile

to consider some of the

theoretical effects

that this unknown variable

might have on the comparison of the effects of 5-AzU and 6-AzU,
fact there

is evidence

that

in

the amount of endogenous orotic acid

is negligible compared to the amount of administered radioactive
orotic acid.
various
lab

Atempts

to measure

the pool size of orotic acid in

tissues have been unsuccessful;

indicate

that it is

less

the results of work in this

,

than 0.1 micromoles/gm in liver.

31

Isotopic dilution studies using radioactive orotic acid have provided
indirect evidence

that the pools of orotic acid

tissues are probably small.

in plasma and

In one study with rats,

38

in

the specific

activity of radioactive orotic acid in the urine was 90% of the
intraperitoneally injected dose

(5.75 micromoles).

Equilibration
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-

with tissue orotic acid, however, was probably only partial.
Although orotic acid can enter the general circulation from the
tissues, as shown by the massive orotic aciduria after blockade of
orotidylic acid decarboxylase by 6-AzUR in human subjects,
amount which normally enters

is apparently very small.

the

Plasma

levels of orotic acid are estimated to be 5 x 10"^ micromoles/ml,
and urinary excretion is only 1.4 mg/day in human subjects.
blockade of orotidylic acid decarboxylase occurs before
tration of radioactive orotic acid,
acid in tissues may be of more
normal concentration.

32

Since

the adminis¬

the rate of formation of orotic

importance

in this study than its

In comparison with the amount of radioactive

orotic acid injected into the rats

in this study, however,

duction of endogenous orotic acid is probably very small.

the pro¬
The pre-

4
viously mentioned study of Koenig, et_ aJ. ,

indicated that a rela¬

tively low rate of synthesis of uridylic acid would maintain the
pool size in the brain.

The concentration of uridylic acid and its

higher phosphate derivatives decreased from 0.25 to 0.14 micromoles/gm
in the brain of an animal treated for 3 days with 1 mg of 6-AzUR per
day by intraventricular injection.
moles/hour, despite the
radioactive orotic acid.

This amounts to only 0.0015 micro¬

75 to 87% blockade of the metabolism of
The rate of synthesis of pyrimidine bases

from orotic acid in the adult human subject has been estimated to
be only 600 mg/day,

32 53
5
a comparatively small amount.

Although it

is probably the case that accumulation of endogenous orotic acid
before or after the administration of radioactive orotic acid is
not significant,

several points may in addition be considered as

32-
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weighing against a significantly different accumulation of orotic
acid in the two treatment groups.

First, the inhibition of its

metabolism is in either case incomplete, being at most 52% (see
below).

Second, a somewhat circular but still pertinent argument

is that if the blockade by 6-AzU (after conversion to 6-AzUMP) be¬
came significantly greater than that by 5-AzU during the hour afte
the injection of radioactive orotic acid, then an equivalent and
compensating accumulation (causing dilution of the radioactive
orotic acid) would have occurred during this hour as occurred in
the hour previous to labelling in the 5-AzU treated animals.

In

conclusion, then, orotic acid in fact probably represents a pharma
cological dose, and not a tracer dose.
Assuming, then, that the model situation applies to rat brain
isotopic dilution with orotic acid provides the most important in¬
formation

about the action of these two inhibitors.

Preliminary

studies showed that orotidylic acid and orotidine are completely
converted to orotic acid by the acid hydrolysis, and that no signi
ficant decomposition of orotic acid occurred during similar treat¬
ment for one hour.
One possible explanation of the 60% greater recovery of acidsoluble activity from the animals treated with 6-AzU (Figure 3) is
found in the markedly different distribution of radioactivity in
these animals.

(Table 2).

Not only did they produce only a few

drops of urine, or none, but they also excreted very little of the
radioactivity in this urine.

The animals treated with 5-AzU or

saline produced at least several milliliters of urine; the animals
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receiving saline also excreted very little of the

radioactivity,

probably because of the rapid metabolism of orotic acid to nucleo14
tides in the

liver.

Respiratory elimination of the

not have been extensive since

C

label would

the 2-carbon is not released until

metabolism of uracil to g-alanine.

In the animals

treated with

6-AzU the conversion of orotic acid into uridine nucleotides
the

liver was also blocked.

in

With the major routes of elimination

and metabolism blocked,

the blood and probably cerebrospinal fluid

levels were

It seems

increased.

likely that hypotension with re¬

sulting poor kidney perfusion could explain the decreased urinary
excretion by these comatose rats,

although specific

such as observed from chronic administration of

tubular damage

1 gm/kg of 6-AzUR

47

may also have been a factor.
The results summarized in the
show that

in control animals

first two columns of Figure 3

the ratio of the sum of orotic acid,

orotidine, and orotidylic acid to the sum
other derivatives was 0.17 as compared to
5-AzU and

1.4 in those

treated with 6-AzU.

of uridylic acid and all
1.1 in rats

treated with

Expressed as a percentage

of radioactive orotic acid undergoing decarboxylation to uridylic
acid,

these values represent 85% + 4%, 47% + 3% and 41% + 5%

respectively.

Inhibition of this conversion was

therefore 45% by

5-AzU, and 52% by 6-AzU.
The results

from paper chromatography did not differ signifi¬

cantly from those above in the

12 animals studied

(Tables 3 and 4).

Uridylic acid and derivatives converted to uridylic acid by acid
hydrolysis were easily distinguishable

from uracil and uridine.
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Chromatographic studies showed

that the conditions of the

hydrolysis,

known to hydrolyze uridine

diphosphate

to the monophosphate,

1 N

triphosphate and uridine

63,64

caused no significant

hydrolysis of uridylic acid or uridine.

The higher phosphate

derivatives and the various sugar derivatives

together were present

in the original extract in an amount approximately equal to the
amount of uridylic acid.

The

fraction of radioactivity contained

in orotidine and orotidylic acid together was obtained by subtrac¬
tion of the amount found in orotic acid before hydrolysis

from that

found after hydrolysis and was 0.7% + 0.5% in control animals,
8.3% + 3.1% and 2.4% + 1.8% in animals
These results,

treated with 5-AzU and 6-AzU.

though not highly significant statistically,

that the orotidylic acid decarboxylase

is

suggest

inhibited by 5-AzU,

and that the formation of orotic acid from orotidylic acid may also
be inhibited.
„ 14
Recovery of radioactivity from 2C-orotic acid in the hydro¬
lyzed ENA fraction varied widely from about
the wash procedure and drug
average value of the
the other values
lated.

the relative

the data to

15%, depending on

However, by taking the

two control animals

to this,

Normalizing

treatment.

1% to

in each group, and relating

incorporation can be calcu¬

1.0 + 0.05 for the control animals,

5-AzU and 6-AzU treated animals were 0.43 + 0.07 and 0.57 + 0.05
respectively.

These compare only approximately to the relative

activity of uridylic acid and all derivatives which were
0.42 + 0.02 and 0„75 + 0.09
animals respectively.

for controls,

1.0 + 0.07,

5-AzU, and 6-AzU treated

Incorporation into DNA appeared to be

than 5% of that into RNA.

less
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CONCLUSIONS

The experiments described above were designed to test

the

hypothesis that the neurological syndrome caused by 6-AzU is the
result of "pyrimidine starvation" as a consequence of the inhibition
of the synthesis of uridylic acid from orotic acid in the brain.
The supporting evidence for this hypothesis has come from showing
considerable interdependence of the neurological and pharmacological
effects of the drug.

The work of Koenig, e_t all. ,

4

and Novotny, et al. ,

in support of this hypothesis has been presented and will be discussed
in more detail below.

It is proposed, however, that the hypothesis

is incorrect if equivalent inhibition of the synthesis of pyrimidines
de novo from orotic acid can be demonstrated in the absence of neuro¬
logical effects.

Demonstration of the converse is less conclusive,

since the neurological effects are less easily definable.
In young white rats, the acute effect of 5-AzU was to create a
metabolic blockade approximately equivalent to that of 6-AzU, but
without causing observable neurological abnormalities.

The drugs were

administered by the same route; both are known to act principally
the conversion of orotic acid to uridylic acid in the brain.

Inhibi¬

tion of this conversion at the time of complete loss of righting
reflex in the rats treated with 6-AzU was marked, and was approx¬
imately equivalent with both drugs.

The completeness of the blockade.

5
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however, is difficult to estimate, not knowing the certainty of the
concentration of orotic acid in normal or treated animals.

If in

fact the injected radioactive orotic acid did contribute signifi¬
cantly to production of uridylic acid, then the degree of "pyrimidine
starvation" was greater in the animals treated with 5AzU than in
those treated with 6-AzU.

In addition, the 60% greater amount of

radioactivity in the brains of the animals treated with 6-AzU may
have tended to overcome the blockade, making inhibition by 6-AzU
appear falsely high.

There is no evidence to suggest, therefore,

that 5-AzU is any less effective an inhibitor or orotic acid meta¬
bolism in the brain than 6-AzU under the present conditions.

The

hypothesis that the neurological effects result from inhibition of
orotic acid metabolism or pyrimidine starvation is judged to be
incorrect in this particular situation.
One of the central issues is whether the short term (hours)
and the long term (days) neurological effects are a result of the
same mechanism.

Certainly the basic signs of somnolence, motor

abnormalities, coma, and characteristic changes in the electro¬
encephalogram observed both chronically and acutely in rats, cats,
and human subjects are basically similar.

In adults receiving

large doses of 6-AzU acutely because of Intestinal breakdown of
6-AzUR, the neurological effects developed rapidly (within a day)f^
Although it cannot be assumed from this that the mechanisms of
long term and short term toxicity are the same, it remains a pos¬
sibility.
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The unusual sensitivity of

the human central nervous system

to very small doses of 6-AzU is not explained adequately by any
theory.

The wide variability of the responses and the doses of

6-AzU required to elicit them seems
to human subjects.

to be a phenomenon limited

This may in part be attributable

to different

schedules of administration and to different underlying disease
states.

Psychological variability may in part explain some of these,

but it is difficult to explain how personality structure per se
could cause variation in such signs as hyperreflexia and coma, or
electroencephalographic changes.

Human subjects differ

from animals

not only in their increased sensitivity to 6-AzU but probably also
in a decreased sensitivity to the central effects of 6-AzUR.

The

latter effect may possibly be explainable on the basis of poor
penetration into brain tissue, but it unlikely that 6-AzUR. could be
more active than 6-AzU in brain tissue of man such as may be the
case in animals.

One would certainly hesitate, however,

to admin¬

ister this drug intrathecally in patients.
Although

long-term administration of the as-triazines

more marked changes in pyrimidine metabolism than does
administration,

causes

short-term

the effect of such interference on brain metabolism

4
in general is not know.

Koenig, ejt al.,

suggested that interfer¬

ence with the role of uridine and cytidine nucleotides as co-factors
in sugar, polysaccharide, and phospholipid metabolism might be the
mechanism causing the disturbance in brain function.
conceivable that the

It is certainly

long term depletion of these pools might be

detrimental to the functioning of the central nervous system, but in
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what way is not known.
the brains of animals

There is no report of anatomic
treated with 6-AzU.

lesions

In dogs administered

mg of 6-AzU/day death occurred by the ninth day, but no
the central nervous system were found on autopsy.
connection,

in

11,31

120

lesions of
In this

it is also of interest that uridine and cytidine in

doses of as much as 2.5 gm in human subjects

failed to reverse the

neurological effects of electroencephalographic changes

in two pa¬

tients with signs of neurological toxicity from 6-AzU.

The role

of RNA is probably less important both neurologically and pharmacologically.

Koenig, et al.,

4

found that the pool of RNA in the brain

was spared despite the 50% decrease in other pyrimidine pools.
o

Incorporation of the radioactivity from 2-

14

C-6-AzU over short

periods of time was not detectable, and incorporation during
periods did not appear to be extensive.

Furthermore,

longer

inhibition of

the synthesis of RNA by 95% with actinomycin D in brain appears
have no neurological consequences.

65

The studies by Novotny, e_t al.
neurological activity of 6-AzUR is
than that of 6-AzU in mice.

to

clearly indicate that the
similar to and probably greater

To what extent the "antineoplastic"

activities and the neurological activities of 6-AzU and 6-AzUR
correspond is a question which deserves

further consideration.

The

similarity of the behavioral changes noted after the intraperitoneal
injection of 6-AzUR to those caused by one-half to one-quarter the
dose of 6-AzU administered by the same route are certainly convincing,
and furthermore,
brain tissue.

the 6-AzUR unquestionably penetrates very poorly into

That it achieves a concentration in the brain only one
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thirty-sixth as great as

that of 6-AzU, however,

With doses of 6-AzUR as great as

10 gm/kg,

seems unlikely.

one might anticipate

slower elimination by the kidneys and maintainance of high blood
levels, and consequently relatively greater penetration into the
brain than the smaller doses of 6-AzU.
tion by Novotny, et_

al.

In addition,

the assump¬

that because 6-AzUR is 20 times more

effective as an anti-neoplastic agent than 6-AzU it must also cause
20 times as great an inhibition of orotidylic acid decarboxylase in
rat brain is probably unjustified.

Nevertheless,

there

is

little

doubt that if only one-tenth as much 6-AzUR reached the brain,
instead of one thirty-sixth,

its activity would still be greater

than that of 6-AzU in mice.

There is also no doubt that it would

be a more active inhibitor of orotidylic acid decarboxylase since
6-AzU must be converted to 6-AzUR before conversion to 6-AzlIMP.
Injection of 6-AzUR intracisternally into a cat caused motor inco¬
ordination when the concentration of 6-AzUR in brain tissue was
0.22 to 0.74 micromoles/gm.

The concentration of 6-AzU in the brains

of the comatose rats in this present experiment was 3.1 micromoles/gm
comparison with the above result suggests that the activities of
6-AzU and 6-AzUR are at least of the same order of magnitude.

Although the results of this study suggest no new hypotheses,
they should by exclusion refocus attention on the barbiturate-like
properties of the as.-triazines.
similarities and differences
effects of these drugs;

There is no problem finding both

in the neurological and pharmacological

for that matter,

the barbiturates differ

among thems elves.
Structurally 6-AzU resembles

the barbiturates.

The series of
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6-alkyl substituted homologs of 6-AzU are even more similar.

These

homologs produce somnolence, and in higher doses, analgesia and
coma;

66

the motor and psychic abnormalities caused by 6-AzU in

patients, however, are not seen with the barbiturates.
tionships among the

lipid solubility,

rapidity of metabolism,

the

The rela¬

the duration of action,

length of the alkyl side chain, and

the hypnotic potency seen in a series of barbiturate homo logs
are also observed with the

5-alkyl substituted triazines

Although lengthening the alkyl substituent increases

decarboxylase.

and presumeably none

69

(Table 6).^

the hypnotic

potency of homologs of 6-AzU, none of the homologs has
anti-tumor activity,

the

significant

inhibits orotidylic acid

A structural difference between the as-triazines

and the barbiturates, however,
both substituents on the

is

that the barbiturates require

5-carbon for neurological activity whereas

homologs of 6-AzU are active only if there

is a single

substituent.

66

The metabolism of 5-ethyl-6-azauracil is predominantly by oxidation
to 5-(l-hydroxyethyl)-6-azauracil, and therefore resembles barbiturate inactivation.
the urine are

68

Only 1 to 3% of the metabolites recovered in

in the form of the ribonucleoside.

suggest that the

increase

It is

tempting to

in neurological activity that occurs with

the addition of the ribose moiety to 6-AzU is a barbiturate-like
property.

However,

the increase in the activity of the barbiturates

with moderately long alkyl substituents

in the 5-position is probably

a result of increased lipid solubility which increases

the amount of

the drug distributed to the brain.

to 6-AzU,

however, decreases

Addition of ribose

its penetration into the brain, and presumeably.
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its

lipid solubility.

6-AzU in having its

The structure of 5-AzU differs

free carbon atom situated between two nitrogen

atoms and in this respect is superficially
Because of the

from that of

less

like

the barbiturates.

low concentration of 5-AzU in brain tissues, however,

an accurate estimation of its potential for neurotoxicity cannot be
made.
The importance of some of the dissimilarities has probably
been over-stressed,
particular,

though certainly there are differences.

the electroencephalogram in animals

and with barbiturates has

In

treated with 6-AzU

important similarities as well as differences.

Neither resembles sleep patterns, and the unusual feature of the
electroencephalogram after administration of 6-AzU is

its resemblance

to that seen in soma or encephalitis, but at a time when no behavioral
effect is observable.
days in patients.

These changes precede somnolence by several

The onset of electroencephalographic changes after

barbiturate administration accompanies

the somnolence.

The changes

in the electroencephalogram after high doses of barbiturates resemble
those after 6-AzU administration; both drugs cause

large-amplitude

random slow waves, depression of photic and acoustic responses,
depression of fast activity, and burst-suppression patterns.

12,69

Since most barbiturates have no anti-convulsant activity it is dif¬
ficult to asses the significance of the antagonism of 6-AzU to nico¬
tine as opposed to pentamethylenetetraazole antagonism seen with bar¬
biturates . ^
Although the effects of these drugs may be similar in many re¬
spects, comparison will be inconclusive as
action of barbiturates

is not understood.

long as

the mechanism of

,

.
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SUMMARY

Intraperitoneal injection of 6-azauracil
rats caused complete

(2 gm/kg)

into young

loss of the righting reflex in about one hour

while an equimolar amount of 5-azauracil did not appear to effect
behavior.
after the

The concentration of 6-azauracil in the brain one hour
loss of righting reflex was six times

and metabolites during the equivalent period.
centration of 6-azauridine

that of 5-azauracil
At this

time the con¬

in the brain was only about 0.7% that of

the 6-azauracil, and 6-azauridylic acid and glyoxylic acid semicarbazone were even less.
2-

14

Incorporation of the radioactivity from

C-6-azauraci 1 into the RNA of the brain was not significant, and

was probably less

than 0.03% of the

total radioactivity in the brain.

The rate of synthesis of pyrimidine nucleotides by slices of cerebral
cortex was measured by the release of
Concentrations of 5-azauracil in the

from 7-^C-orotic acid.
incubation medium equivalent to

those observed in vivo significantly slowed the release of
6-azauracil did not.

14

CC^ but

On a molar basis, however, 6-azauridine was

about one hundred times more effective as an inhibitor of orotic acid
metabolism than 5-azauracil.
nucleotides

The rate of synthesis of pyrimidine

in the brain in vivo was estimated

from the extent to

which ring-labelled orotic acid was converted into uridylic acid
and its metabolites.
orotic

Intracisternal injection of the radioactive

acid was made at the

time of complete

loss of the righting

*

reflex or its equivalent time
or saline.

in the animals administered 5-azauracil

In the animals receiving 5-AzU or saline about

10% of the

injected radioactivity was recovered in an acid extract of the brain
one hour
about

later;

16%.

the recovery from the animals

receiving 6-AzU was

Analysis of the acid-soluble extract of the brain indicated

that uracil, uridine, uridylic acid,

and sugar and higher phosphate

derivatives of uridylic acid constituted 85% of the recovered radio¬
activity in control animals, but only 41 and 47% in thoss administered
6-azauracil and 5-azauracil,
the

respectively.

These results suggest that

loss of the righting reflex, and probably other temporally related

neurological effects of 6-azauracil are

independent of its

of the synthesis de novo of pyrimidines

in the brain.

inhibition

The neurological

and pharmacological properties of 6-azauracil and barbiturates are
compared and the possibility of a barbiturate-like action of 6-azaura¬
cil is discussed.
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TABLE

1.

-

THE CONCENTRATION OF 2-

14

C-5-AZAURACIL AND 2-

14

-C-6-

AZAURACIL AND THEIR METABOLITES IN THE TISSUES OF THE
RAT AFTER INTRAPERITONEAL ADMINISTRATION

Tissue

Micromoles of drug/gm wet tissue
6-azauracil

5-azauracil

hours after injection*

1 (2)
10.9
12.2
3.1
10.7
12.8

whole blood
plasma
whole brain
liver
kidney

2 (4)
9.3
3.8
7.8
13.0

9.2

spleen

9.1

thymus
muscle

7.5

11.9
8.6
6.1

3.6

5.8

*The numbers
each group.

is described

in parentheses

CD

15.1

11.2

intestine

The procedure

1

0.6
2.8
13.0
2.8
3.1
2.5

1.8

2 (1)

4 (1)

1.2
1.7
0.6
1.2
4.5
1.1
1.1
1.2
0.7

0.1
0.2
0.2
0.1
0.5
0.1
0.1
0.2
0.1

in detail under ’’Methods.”
indicate the number of rats

in
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TABLE 2.

-

THE EFFECT OF PREVIOUS ADMINISTRATION OF 5-AZAURACIL
AND 6-AZAURACIL ON THE TISSUE DISTRIBUTION OF RADIO¬
ACTIVITY AFTER INTRACISTERNAL INJECTION OF
2-14C-OROTIC ACID

Radioactivity

Pretreatment

_3
cpm/ml x 10 '

Total cpm x 10

Saline
5- azauracil
6- azauracil

Brain

Liver

Urine

Blood

352 + 55
318 + 24
583 + 100

1140 + 290
322 + 20
286 + 25

108 + 53
1050 + 200
50 + 44

10.4 + 1.2
13.4 + 2.0
18.8 + 4.0

14„
The animals were administered 0.5 micromoles of 2- C-orotic
£
acid, 3.3 x 10° cpm, by intracisternal injection 1 hour before
sacrifice.
The procedure is described more fully under "Methods.'
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TABIE 3.

-

RESOLUTION OF SEIECTED PYRIMIDINES AND TRIAZINES
IN THREE SOLVENT SYSTEMS

Compound

Rf x 100
Solvent systems
(1)

(2)

(3)

6-Azauracil
6-Azauridine
6-Azauridylic acid
Glyoxylic acid semicarbazone
5-Azauracil

59
40
13
52
43

71
63
14
36
63

63
50
28
41
--

Dihydroorotic acid
Orotic acid
Orotidine
Orotidylic acid

34
25
18
8

35
50
42
12

30
29
14

Uridylic acid
Uridine diphosphate
Uridine triphosphate
Uridine diphosphate glucose
Uridine diphosphate glucosamine
Uridine
Uracil

16
9
6
6
6
42
54

20
17
14
24
28
73
70

30
--12
16
60
69

- «

The solvent systems are:
(1) n-butanol, glacial acetic
acid, and water, 5:1:2;
(2) n-butanol, pyridine, and water,
1:1:1; and (3) iso-butyric acid, 2 N ammonium hydroxide, and
water, 85:1.3:15.
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TAB IE 4.

COMPARISON OF THE DATA OBTAINED BY PAPER CHROMATOGRAPHY
(TABIE 4) TO THOSE OBTAINED BY ISOTOPIC DILUTION

Pretreatment

Percentage of the total radioactivity of the
acid extract of brain present as orotic acid
after acid hydrolysis.
By paper
chromatography
(average)

Saline
5-Azauracil
6-Azauracil

14.7 + 4.9
54.7 + 5.0
60.6 + 2.6

(4)
(4)
(4)

By isotopic dilution

14.3 + 3.5
55.1 + 2.0
60.9 + 3.7

(4)
(4)
(4)

14.9 + 4.4
52.8 + 3.3
58.5 +4.7

The numbers in parentheses indicate the number of animals in
each group;
the data in the first two columns are from the same
animals; the third column shows the result for all 21 animals.

(6)
(8)
(7)

TAB IE 5.

Compound
6-Azauracil
5-Methy1-6azauracil
5-Ethyl-6azauracil
5-Propyl-6azauracil

COMPARISON OF HYPNOTIC POTENCY AND PHARMACOLOGICAL
PROPERTIES OF 6-AZAURACIL AND ALKYL DERIVATIVES*

Relative
mo lar
potency
in mice

Time of
onset of
hypnosis
in min.

Re lative
distri¬
bution
coefficient
EtAcrpH 7.3
buffer

Duration
of hypnosis
in hours

Percent
Me tab olized
in 24
hours

*

1.0

45-60

1.0

4-8

0-10

2.7

20-30

3.1

2-3

20

5.0

18-20

7.9

hr 1

73

8.2

8-12

12.1

%-2

87

Unpublished data of R. E. HandSchumacher.
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Figure 1.
Summary of pyrimidine metabolism in mammals and the
action of 6-azauracil.
Abbreviations: USA, ureidosuccinic acid;
DHOA, dihydroorotic acid;
OA, orotic acid;
OR, orotidine;
OMP,
orotidylic acid; PRPP, 5-phosphoribosyl-l-pyrophosphate;
PP,
inorganic pyrophosphate;
UMP, uridylic acid;
UR, uridylic acid;
U, uracil; UUP, uridine diphosphate;
dUDP, deoxyuridine diphos¬
phate;
dUMP, deoxyuridine monophosphate;
UTP, uridine triphos¬
phate; CTP, cytidine triphosphate;
CDP, cytidine diphosphate;
dCDP, deoxycytidine diphosphate;
dCTP, deoxycytidine triphosphase;
TMP, thymidine monophosphate; TDP, thymidine diphosphate; TTP,
thymidine triphosphate; UDPX, uridine diphosphate sugar deriva¬
tives;
CDPX, cytidine diphosphate sugar derivatives.

TDP^--=s= TTP

Aspartate ♦ Carbamylphosphate

dCTP
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Figure 2.
The effect
5-azauraci j.. 6-azauracil, and 6-azauridine on the release of
CO2 from 7- u-orotic acid, 0.05 micro¬
moles/ml, by tissue slices from the cerebral cortex of rats, 30
min. incubation. Each symbol represents a single determination.
The mean value and standard deviation is indicated for 9 control
animals.

25

CONTROLS
20

15

A

6-AzU

O

5-AzU

□

6-AzUR

10

05

0

j_i_I_i_I

3

1

0.3

0.1

MOLARITY OF INHIBITOR X 103

0.03
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Figure 3.
The effect of 5-azauracil, 2g/kg, and 6-azauracil,
2g/kg, on the metabolism of 7-^C-orotic acid (0.45 micromoles,
3.3 x 10^ cpm) administered into the cisterna magna of rats.
The numbers in parentheses indicate the number of animals in
each group. Abbreviations are defined on p. 15.
The procedure
is described under "Methods.1'

C PM

CONTROL (7)

5-AZU (8)

6-AZU

(6)
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